利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

77 条记录 (耗时 0.047 秒)

    Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
    51.
    发明申请
    Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient 有权
    含氮杂环衍生物和含有与活性成分相同的药物

    公开(公告)号：US20060178399A1

    公开(公告)日：2006-08-10

    申请号：US10549120

    申请日：2004-03-12

    申请人： Rena Nishizawa ,  Yoshikazu Takaoka ,  Shiro Shibayama

    发明人： Rena Nishizawa ,  Yoshikazu Takaoka ,  Shiro Shibayama

    IPC分类号： A61K31/4545 ,  A61K31/454 ,  C07D417/02 ,  C07D403/02 ,  C07D401/02

    CPC分类号： C07D211/32 ,  C07D211/22 ,  C07D211/34 ,  C07D211/48 ,  C07D211/58 ,  C07D211/62 ,  C07D211/66 ,  C07D211/72 ,  C07D211/74 ,  C07D241/04 ,  C07D295/108 ,  C07D401/04 ,  C07D401/06 ,  C07D401/08 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D487/08

    摘要： A compound represented by the following general formula (I), its salt, solvates thereof or prodrugs thereof: (wherein each symbol is as defined in the description.) The compounds represented by the general formula (I) are useful in preventing and/or treating various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis, etc.), infection with human immunodeficiency virus (acquired immunodeficiency syndrome, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchoplumonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis and so on.

    摘要翻译： 由以下通式（I）表示的化合物，其盐，溶剂合物或其前药：（其中每个符号如说明书中所定义）。由通式（I）表示的化合物可用于预防和/或 治疗各种炎性疾病（哮喘，肾炎，肾病，肝炎，关节炎，类风湿性关节炎，鼻炎，结膜炎，溃疡性结肠炎等），免疫疾病（器官移植中的自身免疫性疾病，排斥反应，免疫抑制，牛皮癣，多发性硬化症等） ，人类免疫缺陷病毒（获得性免疫缺陷综合征等）感染，过敏性疾病（特应性皮炎，荨麻疹，过敏性支气管曲霉曲霉菌，过敏性嗜酸性胃肠炎等），缺血再灌注损伤，急性呼吸窘迫综合征，伴随细菌感染的休克，糖尿病 ，癌转移等。

    MULTIMER OF EXTRACELLULAR DOMAIN OF CELL SURFACE FUNCTIONAL MOLECULE
    54.
    发明申请
    MULTIMER OF EXTRACELLULAR DOMAIN OF CELL SURFACE FUNCTIONAL MOLECULE 有权
    细胞表面功能分子的细胞域的多个

    公开(公告)号：US20120269859A1

    公开(公告)日：2012-10-25

    申请号：US13486189

    申请日：2012-06-01

    申请人： Nagahiro Minato ,  Yoshimasa Tanaka ,  Shiro Shibayama

    发明人： Nagahiro Minato ,  Yoshimasa Tanaka ,  Shiro Shibayama

    IPC分类号： C07K14/435 ,  A61P35/00 ,  A61K39/00 ,  A61P37/00 ,  A61P31/00 ,  A61K38/17 ,  A61P35/04

    CPC分类号： C07K14/70503 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/00 ,  A61K47/26 ,  C07K14/70532 ,  Y02A50/465 ,  Y02A50/481

    摘要： As a substance which pharmacologically regulates the function of a cell surface functional molecule, a substance which has specificity and an activity or efficacy equal or superior to an antibody and does not require an advanced production technique and facility for application thereof to a pharmaceutical product has been demanded. The invention relates to a multimer of an extracellular domain of a cell surface functional molecule, particularly a tetramer of an extracellular domain of PD-1 or PD-L1. Further, the invention relates to an application of such a tetramer as a preventive and/or therapeutic agent for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.

    摘要翻译： 作为药理学上调节细胞表面功能分子的功能的物质，具有特异性，活性或功效等同于或优于抗体且不需要先进的生产技术的物质及其应用于药物的设备已经被 要求 本发明涉及细胞表面功能分子的细胞外结构域的多聚体，特别是PD-1或PD-L1细胞外结构域的四聚体。 此外，本发明涉及这样的四聚体作为癌症，癌症转移，免疫缺陷，感染性疾病等的预防和/或治疗剂的应用，以及应用PD-1或PD-L1作为检测或诊断 代理人或这种疾病的研究代理人。

    Multimer of extracellular domain of cell surface functional molecule
    55.
    发明授权
    Multimer of extracellular domain of cell surface functional molecule 有权
    细胞表面功能分子细胞外结构域的多聚体

    公开(公告)号：US08216996B2

    公开(公告)日：2012-07-10

    申请号：US12281427

    申请日：2007-03-02

    申请人： Nagahiro Minato ,  Yoshimasa Tanaka ,  Shiro Shibayama

    发明人： Nagahiro Minato ,  Yoshimasa Tanaka ,  Shiro Shibayama

    IPC分类号： A61K38/00

    CPC分类号： C07K14/70503 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/00 ,  A61K47/26 ,  C07K14/70532 ,  Y02A50/465 ,  Y02A50/481

    摘要： As a substance which pharmacologically regulates the function of a cell surface functional molecule, a substance which has specificity and an activity or efficacy equal or superior to an antibody and does not require an advanced production technique and facility for application thereof to a pharmaceutical product has been demanded. The invention relates to a multimer of an extracellular domain of a cell surface functional molecule, particularly a tetramer of an extracellular domain of PD-1 or PD-L1. Further, the invention relates to an application of such a tetramer as a preventive and/or therapeutic agent for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.

    摘要翻译： 作为药理学上调节细胞表面功能分子的功能的物质，具有特异性，活性或功效等同于或优于抗体且不需要先进的生产技术的物质及其应用于药物的设备已经被 要求 本发明涉及细胞表面功能分子的细胞外结构域的多聚体，特别是PD-1或PD-L1细胞外结构域的四聚体。 此外，本发明涉及这样的四聚体作为癌症，癌症转移，免疫缺陷，感染性疾病等的预防和/或治疗剂的应用，以及应用PD-1或PD-L1作为检测或诊断 代理人或这种疾病的研究代理人。

    NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF
    58.
    发明申请
    NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF 失效
    硝基杂环化合物及其药物用途

    公开(公告)号：US20090233908A1

    公开(公告)日：2009-09-17

    申请号：US11816940

    申请日：2006-02-24

    申请人： Hiroshi Ochiai ,  Akira Ohhata ,  Yoshikazu Takaoka ,  Shiro Shibayama

    发明人： Hiroshi Ochiai ,  Akira Ohhata ,  Yoshikazu Takaoka ,  Shiro Shibayama

    IPC分类号： A61K31/55 ,  C07D403/14 ,  C07D401/14 ,  A61K31/506

    CPC分类号： A61K45/06 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14

    摘要： A compound represented by formula (I): (wherein the symbols are the same as defined in the description), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medicinal use thereof.The compound represented by formula (I) has CXCR4 antagonistic activity. It is hence useful as, e.g., a preventive and/or therapeutic agent for CXCR4-mediated diseases such as inflammatory/immunologic diseases (e.g., rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, and rejection reactions of transplanted organs), allergic diseases, infections diseases (e.g., human immunodeficiency virus infection and acquired immunologic deficiency syndrome), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease, metabolic diseases, cancer diseases (e.g., cancer, cancer metastasis) or as an agent for regeneration therapy.

    摘要翻译： 由式（I）表示的化合物：其中符号与说明书中定义相同，其盐，其N-氧化物，其溶剂合物或其前药，及其药物用途。 由式（I）表示的化合物具有CXCR4拮抗活性。 因此，其可用作例如CXCR4介导的疾病如炎症/免疫疾病（例如类风湿性关节炎，关节炎，视网膜病变，肺纤维化和移植器官的排斥反应）的预防和/或治疗剂，过敏性疾病， 感染疾病（例如人类免疫缺陷病毒感染和获得性免疫缺陷综合征），精神神经病，脑疾病，心脏/血管疾病，代谢疾病，癌症疾病（例如癌症，癌症转移）或再生治疗剂。

    Nitrogenous Heterocylic Derivative and Medicine Containing the Same as an Active Ingredient
    60.
    发明申请
    Nitrogenous Heterocylic Derivative and Medicine Containing the Same as an Active Ingredient 有权
    含氮异构衍生物和含有与活性成分相同的药物

    公开(公告)号：US20080057074A1

    公开(公告)日：2008-03-06

    申请号：US11662639

    申请日：2005-09-12

    申请人： Yoshikazu Takaoka ,  Shiro Shibayama ,  Rena Nishizawa

    发明人： Yoshikazu Takaoka ,  Shiro Shibayama ,  Rena Nishizawa

    IPC分类号： C07D401/02 ,  A61K31/4427 ,  A61K31/444 ,  A61K31/4523 ,  A61K31/5377 ,  A61K31/55 ,  C07D401/14 ,  C07D451/02 ,  C07D413/02 ,  A61K39/21 ,  A61K39/42 ,  A61P31/12 ,  A61P31/18 ,  C07D211/68

    CPC分类号： C07D413/12 ,  A61K31/00 ,  C07D211/58 ,  C07D231/12 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D409/14

    摘要： A compound represented by formula (I), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof: (wherein each symbol is as defined in the description.) The compounds represented by formula (I) has the antagonistic activity against CCR5, so they are useful in preventing and/or treating CCR5-related diseases, for example, various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, inflammatory bowel disease such as ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation (rejection of graft of solid organ, rejection of graft of pancreatic islet cells in therapy for diabetes, graft-versus-host disease, etc.), immunosuppression, psoriasis, multiple sclerosis, etc.), infectious diseases (infection with human immunodeficiency virus, acquired immunodeficiency syndrome, infection with RSV, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), cardiovascular diseases (arteriosclerosis, ischemic reperfusion injury, etc.), acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis and so on.

    摘要翻译： 由式（I）表示的化合物，其盐，其N-氧化物，其溶剂合物或其前药：（其中各符号如说明书中所定义）。式（I）表示的化合物具有拮抗作用 因此它们可用于预防和/或治疗CCR5相关疾病，例如各种炎性疾病（哮喘，肾炎，肾病，肝炎，关节炎，类风湿关节炎，鼻炎，结膜炎，炎性肠病如溃疡性结肠炎） 等等），免疫疾病（自身免疫性疾病，器官移植排斥反应（实体器官移植排斥反应，胰岛细胞移植对糖尿病的治疗排斥反应，移植物抗宿主病等），免疫抑制，牛皮癣， 多发性硬化症等），感染性疾病（人类免疫缺陷病毒感染，获得性免疫缺陷综合征，RSV感染等），过敏性疾病（特应性皮炎，荨麻疹，过敏性 急性呼吸窘迫综合征，伴随细菌感染的休克，糖尿病，癌症转移等），心血管疾病（动脉硬化，缺血再灌注损伤等）。